Related Experiment Videos
Effects of riluzole on the evolution of focal cerebral ischemia: a magnetic resonance imaging study
I Mottet1, R Demeure, J Rataud
1Department of Radiology and Medical Imaging, Université Catholique de Louvain, Brussels, Belgium.
Abstract:
The aim of this study was to investigate the effects of riluzole on the lesion induced by a permanent middle cerebral artery occlusion (MCAO) in rats. Riluzole at 4 or 8 mg/kg i.v. significantly reduced the cortical ischemic brain damage. With the most effective dose of 8 mg/kg, the time evolution of the lesion was assessed by T2-weighted magnetic resonance imaging (MRI) repeated on the same animals after MCAO. MRI obtained at 24, 48, and 72 hours after MCAO showed a progressive increase of the ischemic lesion, except in the cortex of the riluzole-treated rats (8 mg/kg i.v.). Furthermore, there was no difference between lesion volumes as measured by MRI or by histology. This study indicates that MRI may be a valuable method to quantify in vivo the neuroprotective profile of a drug.
Insights
Riluzole effectively reduced ischemic brain damage in rats following middle cerebral artery occlusion (MCAO). Magnetic resonance imaging (MRI) confirmed riluzole
Area of Science:
- Neuroscience
- Pharmacology
- Medical Imaging
Background:
- Ischemic stroke, caused by middle cerebral artery occlusion (MCAO), leads to significant brain damage.
- Riluzole is a neuroprotective agent with potential therapeutic applications in stroke.
- Accurate in vivo assessment of neuroprotective drug efficacy is crucial.
Purpose of the Study:
- To investigate the neuroprotective effects of riluzole on MCAO-induced ischemic brain lesions in rats.
- To evaluate the utility of T2-weighted magnetic resonance imaging (MRI) for quantifying drug-induced neuroprotection in vivo.
Main Methods:
- Rats underwent permanent MCAO to induce ischemic stroke.
- Riluzole was administered intravenously at doses of 4 or 8 mg/kg.
- T2-weighted MRI was used to monitor lesion volume at 24, 48, and 72 hours post-MCAO. Histological analysis was performed for comparison.
Main Results:
- Riluzole significantly reduced cortical ischemic brain damage at both 4 and 8 mg/kg doses.
- The 8 mg/kg dose of riluzole prevented the progressive increase of the ischemic lesion observed in control animals.
- MRI-measured lesion volumes correlated well with histological findings, demonstrating MRI's accuracy.
Conclusions:
- Riluzole exhibits significant neuroprotective effects against MCAO-induced ischemic brain injury in rats.
- T2-weighted MRI is a valuable tool for in vivo quantification of neuroprotective drug efficacy.
- This study supports further investigation of riluzole as a potential therapeutic agent for ischemic stroke.